BioNTech (BNTX) Q3 2026 (EUR): Revenue 1.29bln (exp. 1.03bln). Narrows its FY26 revenue guidance to 1.7-1.9bln (exp. 1.8bln, prev. 1.6-1.9bln)

• Future R&D costs under the collaboration with Roche (ROP SW) will be assigned to Roche.

The headline print is a sizeable top-line beat, but for this company the quarter-to-quarter revenue line has long been secondary to the guidance corridor and the cost base, since pandemic-era vaccine income has been on a managed decline and the investment case rests on the oncology pipeline. Narrowing the FY range by lifting the floor while leaving the midpoint essentially at consensus is the less aggressive form of a guidance raise; in past episodes of this pattern the market has treated it as confirmation rather than upgrade, with the reaction hinging on how much of the beat is vaccine seasonality versus durable revenue. The more structurally significant line is the transfer of future R&D costs under the Roche collaboration to the partner: cost reassignment of this kind improves reported opex and cash burn optics but typically reflects a rebalancing of economics within the partnership, so the detail on which programmes are covered and how milestones and profit shares are affected matters more than the headline saving. Revenue composition is the other tell, in particular the split between the partnered COVID franchise, where the company books only a share of economics, and any early non-vaccine contribution. Worth watching are the call commentary on the collaboration terms, gross-to-net and demand assumptions behind the narrowed range, and any update to the oncology readout calendar, which is where the re-rating or de-rating cases have historically been made.